| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 1.69% | Piper Sandler | $220 → $215 | Maintains | Neutral |
| 09/25/2023 | 18.25% | Stephens & Co. | → $250 | Reiterates | Overweight → Overweight |
| 09/01/2023 | 25.34% | JMP Securities | $240 → $265 | Maintains | Market Outperform |
| 08/03/2023 | 6.42% | Morgan Stanley | $206 → $225 | Maintains | Equal-Weight |
| 08/03/2023 | 22.03% | Keybanc | $254 → $258 | Maintains | Overweight |
| 08/02/2023 | 13.52% | JMP Securities | → $240 | Reiterates | Market Outperform → Market Outperform |
| 07/25/2023 | 20.14% | Keybanc | $235 → $254 | Maintains | Overweight |
| 07/17/2023 | 18.25% | Stephens & Co. | $240 → $250 | Maintains | Overweight |
| 05/30/2023 | -2.56% | Morgan Stanley | → $206 | Initiates Coverage On | → Equal-Weight |
| 05/12/2023 | -5.4% | Piper Sandler | $197 → $200 | Maintains | Neutral |
| 05/12/2023 | 11.15% | Keybanc | $210 → $235 | Maintains | Overweight |
| 05/11/2023 | 13.52% | JMP Securities | → $240 | Reiterates | Market Outperform → Market Outperform |
| 04/14/2023 | -6.82% | Piper Sandler | $215 → $197 | Downgrades | Overweight → Neutral |
| 02/15/2023 | 13.52% | JMP Securities | $250 → $240 | Maintains | Market Outperform |
| 02/10/2023 | 1.69% | Piper Sandler | $235 → $215 | Maintains | Overweight |
| 02/09/2023 | 4.06% | Stephens & Co. | → $220 | Maintains | Overweight |
| 11/11/2022 | -0.67% | Keybanc | $240 → $210 | Maintains | Overweight |
| 09/23/2022 | — | Needham | Downgrades | Buy → Hold | |
| 08/04/2022 | 12.1% | Needham | $248 → $237 | Maintains | Buy |
| 08/04/2022 | 13.52% | Keybanc | $256 → $240 | Maintains | Overweight |
| 07/14/2022 | 13.52% | Piper Sandler | → $240 | Initiates Coverage On | → Overweight |
| 05/13/2022 | 17.3% | Needham | $263 → $248 | Maintains | Buy |
| 02/14/2022 | 27.71% | JMP Securities | $250 → $270 | Maintains | Market Outperform |
| 02/10/2022 | 24.4% | Needham | $254 → $263 | Maintains | Buy |
| 11/04/2021 | 27.71% | Stephens & Co. | $255 → $270 | Maintains | Overweight |
| 11/04/2021 | 21.09% | Keybanc | $239 → $256 | Maintains | Overweight |
| 08/11/2021 | 18.25% | Baird | $230 → $250 | Maintains | Outperform |
| 08/11/2021 | 20.61% | Stephens & Co. | $217 → $255 | Maintains | Overweight |
| 08/11/2021 | 13.05% | Keybanc | $227 → $239 | Maintains | Overweight |
| 05/26/2021 | 10.21% | Needham | → $233 | Upgrades | Hold → Buy |
| 05/11/2021 | 11.15% | JMP Securities | $217 → $235 | Maintains | Market Outperform |
| 03/11/2021 | 7.37% | Keybanc | $224 → $227 | Maintains | Overweight |
| 02/04/2021 | 5.95% | Keybanc | → $224 | Upgrades | Sector Weight → Overweight |
| 09/02/2020 | -17.23% | Baird | → $175 | Initiates Coverage On | → Outperform |
| 06/09/2020 | — | Needham | Initiates Coverage On | → Hold | |
| 03/23/2020 | -31.42% | Stephens & Co. | $177 → $145 | Maintains | Overweight |
| 02/12/2020 | -16.28% | Stephens & Co. | $165 → $177 | Maintains | Overweight |
| 07/10/2019 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 05/22/2019 | -29.05% | JMP Securities | $135 → $150 | Maintains | Market Outperform |
| 05/15/2019 | -34.73% | Keybanc | $135 → $138 | Maintains | Overweight |
| 12/06/2018 | -25.74% | Sidoti & Co. | $155 → $157 | Maintains | Buy |
| 11/13/2018 | -37.57% | Keybanc | $120 → $132 | Maintains | Overweight |
What is the target price for Steris (STE)?
The latest price target for Steris (NYSE: STE) was reported by Piper Sandler on October 26, 2023. The analyst firm set a price target for $215.00 expecting STE to rise to within 12 months (a possible 1.69% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Steris (STE)?
The latest analyst rating for Steris (NYSE: STE) was provided by Piper Sandler, and Steris maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Steris (STE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Steris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Steris was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating Steris (STE) correct?
While ratings are subjective and will change, the latest Steris (STE) rating was a maintained with a price target of $220.00 to $215.00. The current price Steris (STE) is trading at is $211.42, which is out of the analyst's predicted range.